TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
NGNE

Neurogene Inc

Healthcare · Biotechnology · —

28.30$ -9.4% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

Neurogene Inc (NGNE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 244 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet NGNE
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
90 223 195 180 164 336 315 297 288 289 263 244
80 200 174 159 144 316 296 279 271 272 247 229
25 148 150 111 67 137 71 59 71 104 124 112
79 197 170 154 139 312 293 275 265 269 243 225
– 0.6 0.6 0.6 0.7 0.6 0.6 1.3 0.9 0.5 – –
14 37 25 25 27 25 24 24 22 24 25 27
5.2 23 12 13 16 15 14 15 15 16 19 22
2.3 2.9 2.7 2.8 3.7 3.0 4.2 4.3 3.7 3.1 3.0 3.0
2.1 2.6 1.5 1.7 1.7 1.3 3.1 2.1 1.5 2.0 4.7 3.3
75 186 171 155 137 310 292 273 266 265 238 217
-472 -187 -204 -223 -243 -262 -285 -307 -328 -353 -384 -418
11 13 17 17 17 15 21 21 21 15 22 23

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?